22nd Century EPS - Earnings per Share 2011-2024 | XXII
22nd Century eps - earnings per share from 2011 to 2024. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| 22nd Century Annual EPS |
| 2023 |
$-116.48 |
| 2022 |
$-74.40 |
| 2021 |
$-50.38 |
| 2020 |
$-33.58 |
| 2019 |
$-50.38 |
| 2018 |
$-14.39 |
| 2017 |
$-31.18 |
| 2016 |
$-35.98 |
| 2015 |
$-38.38 |
| 2014 |
$-62.37 |
| 2013 |
$-143.93 |
| 2012 |
$-52.77 |
| 2011 |
$-11.99 |
| 2010 |
$-26.39 |
| 22nd Century Quarterly EPS |
| 2024-09-30 |
$-0.55 |
| 2024-06-30 |
$-0.21 |
| 2024-03-31 |
$-2.94 |
| 2023-12-31 |
$-10.43 |
| 2023-09-30 |
$-60.75 |
| 2023-06-30 |
$-23.81 |
| 2023-03-31 |
$-21.49 |
| 2022-12-31 |
$-32.17 |
| 2022-09-30 |
$-15.04 |
| 2022-06-30 |
$-15.20 |
| 2022-03-31 |
$-11.99 |
| 2021-12-31 |
$-21.59 |
| 2021-09-30 |
$-14.39 |
| 2021-06-30 |
$-7.20 |
| 2021-03-31 |
$-7.20 |
| 2020-12-31 |
$-9.60 |
| 2020-09-30 |
$-7.20 |
| 2020-06-30 |
$-9.60 |
| 2020-03-31 |
$-7.20 |
| 2019-12-31 |
$-11.99 |
| 2019-09-30 |
$-19.19 |
| 2019-06-30 |
$-14.39 |
| 2019-03-31 |
$-4.80 |
| 2018-12-31 |
$-14.39 |
| 2018-09-30 |
$9.60 |
| 2018-06-30 |
$-11.99 |
| 2018-03-31 |
$2.40 |
| 2017-12-31 |
$-7.20 |
| 2017-09-30 |
$-7.20 |
| 2017-06-30 |
$-9.60 |
| 2017-03-31 |
$-7.20 |
| 2016-12-31 |
$-9.60 |
| 2016-09-30 |
$-7.20 |
| 2016-06-30 |
$-9.60 |
| 2016-03-31 |
$-9.60 |
| 2015-12-31 |
$-9.60 |
| 2015-09-30 |
$-9.60 |
| 2015-06-30 |
$-4.80 |
| 2015-03-31 |
$-14.39 |
| 2014-12-31 |
$-21.59 |
| 2014-09-30 |
$-11.99 |
| 2014-06-30 |
$-7.20 |
| 2014-03-31 |
$-21.59 |
| 2013-12-31 |
$-47.98 |
| 2013-09-30 |
$-76.76 |
| 2013-06-30 |
$-2.40 |
| 2013-03-31 |
$-16.79 |
| 2012-12-31 |
$-31.18 |
| 2012-09-30 |
$-2.40 |
| 2012-06-30 |
$0.00 |
| 2012-03-31 |
$-19.19 |
| 2011-12-31 |
$9.60 |
| 2011-09-30 |
$-4.80 |
| 2011-06-30 |
$-9.60 |
| 2011-03-31 |
$-7.20 |
| 2010-12-31 |
$0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Consumer Staples |
Tobacco Products |
$0.005B |
$0.032B |
|
22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company's products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York.
|
